We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

ELISA Kit Accurately Detects Bioactive Hepcidin Levels

By LabMedica International staff writers
Posted on 17 Aug 2015
Print article
The DRG Hepcidin 25 HS enzyme-linked immunosorbent assay (ELISA) kit
The DRG Hepcidin 25 HS enzyme-linked immunosorbent assay (ELISA) kit (Photo courtesy of DRG International - Biocheck)
An enzyme-linked immunosorbent assay (ELISA) kit has been introduced that accurately detects bioactive hepcidin levels as an additional marker to aid in identifying a variety of disorders.

Hepcidin has been identified as a factor in regulating the amount of iron in humans and unbalanced iron level can lead to many common medical conditions including anemia and iron overload disease, and can occur in chronic kidney disease, inflammation, or diabetes mellitus.

The new Hepcidin 25 (bioactive) HS ELISA kit has an analytical sensitivity of 0.153 ng/mL, with a measuring range of 0 81 ng/mL to 153 ng/mL. Serum or plasma samples can be assessed and the total incubation time is less than two hours. The ELISA is user-friendly as no shaker and no assay buffer is required, and all reagents except wash solution are ready-to-use.

The new DRG Hepcidin 25 (bioactive) HS (High Sensitive) ELISA Kit is manufactured by DRG International (Springfield Township, NJ, USA) and is more sensitive that their previous product for measuring hepcidin. The DRG Hepcidin 25 (bioactive) HS ELISA Kit is available worldwide, providing a simple, fast and accurate method to test hepcidin levels. The measurement results of this kit offer more information to help treat medical issues including iron deficiency diseases, which are some of the most common diseases worldwide. The ELISA kit is Conformité Européenne (CE) marked.

Cyril E. Geacintov, PhD, founder, president and CEO of DRG International, said, “We at DRG International saw the need for an accurate and easy to use hepcidin testing kit and are encouraged by the great success that our customers have seen using the product. This kit is an important step to meet the rapidly growing worldwide interest in hepcidin testing and the applications of that testing in the health and wellness community.”

The new Hepcidin ELISA kit was showcased at the American Association for Clinical Chemistry (AACC) annual meeting held from July 27-30, 2015, in Atlanta (Georgia, USA).

Related Links:

DRG International


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
TORCH Panel Rapid Test
Rapid TORCH Panel Test
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get complete access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: Molecular PCR-grade detection of Lyme bacteria right at the tick bite (Photo courtesy of En Carta Diagnostics)

Groundbreaking Molecular Diagnostic Kit to Provide Lyme Disease Detection in Minutes

Lyme disease, transmitted through tick bites, is a bacteria-caused illness that impacts 1.2 million individuals annually. The standard methods for diagnosing this disease include clinical examinations,... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: The novel test uses an existing diagnostic procedure as its basis to target the Epstein Barr Virus (Photo courtesy of 123RF)

Blood Test Measures Immune Response to Epstein-Barr Virus in MS Patients

Multiple sclerosis (MS) is a chronic neurological condition for which there is currently no cure. It affects around three million people globally and ranks as the second most common cause of disability... Read more

Microbiology

view channel
Image: The T-SPOT.TB test is now paired with the Auto-Pure 2400 liquid handling platform for accurate TB testing (Photo courtesy of Shutterstock)

Integrated Solution Ushers New Era of Automated Tuberculosis Testing

Tuberculosis (TB) is responsible for 1.3 million deaths every year, positioning it as one of the top killers globally due to a single infectious agent. In 2022, around 10.6 million people were diagnosed... Read more

Pathology

view channel
Image: Insulin proteins clumping together (Photo courtesy of Jacob Kæstel-Hansen)

AI Tool Detects Tiny Protein Clumps in Microscopy Images in Real-Time

Over 55 million individuals worldwide suffer from dementia-related diseases like Alzheimer's and Parkinson's. These conditions are caused by the clumping together of the smallest building blocks in the... Read more

Industry

view channel
Image: For 46 years, Roche and Hitachi have collaborated to deliver innovative diagnostic solutions (Photo courtesy of Roche)

Roche and Hitachi High-Tech Extend 46-Year Partnership for Breakthroughs in Diagnostic Testing

Roche (Basel, Switzerland) and Hitachi High-Tech (Tokyo, Japan) have renewed their collaboration agreement, committing to a further 10 years of partnership. This extension brings together their long-standing... Read more